jing

Anticancer Bioscience Announces its First Granted US Patent for Synthetic Lethal Approach to Identifying Novel Cancer Treatments

6,411 Comments / Press Releases / By
In the NewsChengdu, China, September 9, 2021Anticancer Bioscience Announces its First Granted US Patent for Synthetic Lethal Approach to Identifying Novel Cancer Treatments Anticancer Bioscience (ACB), pioneers in synthetic lethal approaches to precision oncology, announced today its first granted US patent (11104633), entitled “cancer treatment using compounds that selectively target polyploid cancer cells for disruption”, which was issued …

Anticancer Bioscience Announces its First Granted US Patent for Synthetic Lethal Approach to Identifying Novel Cancer Treatments Read More »

Anticancer Bioscience Appoints Leader in Oncology Drug Development, Dr. Hong Liu, as US-based VP of Clinical Development

48 Comments / Press Releases / By
In the NewsChengdu, China, 14 July 2021Anticancer Bioscience Appoints Leader in Oncology Drug Development, Dr. Hong Liu, as US-based VP of Clinical Development Anticancer Bioscience (ACB), pioneers in synthetic lethal approaches to precision oncology, announced today appointment of Dr. Hong Liu as VP of Clinical Development. A physician-scientist, he will be based in Chengdu and …

Anticancer Bioscience Appoints Leader in Oncology Drug Development, Dr. Hong Liu, as US-based VP of Clinical Development Read More »

Anticancer Bioscience Announces Preclinical Data of Lead Compounds Against Novel Myc Synthetic Lethal Target in Cancer

1,077 Comments / Press Releases / By
In the NewsMay 11, 2021Anticancer Bioscience Announces Preclinical Data of Lead Compounds Against Novel Myc Synthetic Lethal Target in Cancer Unique target for MYC-SL compounds identified for precision oncology Three classes of novel synthetic lethal compounds (MYC-SL) identified against this target, acting through interfering mitosis and blocking cytokinesis Therapeutic efficacy demonstrated in a large panel …

Anticancer Bioscience Announces Preclinical Data of Lead Compounds Against Novel Myc Synthetic Lethal Target in Cancer Read More »

BioForward 2021

Event / By
BioForward 2021 BioForward is a packed one-day event that provides R&D business leaders with the knowledge, skills, connectivity and services required to achieve sustainable commercial success.

BioDigital 2021

Event / By
BioDigital 2021 BIO Digital is the world’s largest virtual biotech partnering and education event, convening thousands of global biotech leaders and innovators. Join us in our efforts to accelerate a BIO-Revolution through global partnerships, collaboration, and thought leadership.

BIO€QUITY Europe

Event / By
Europe’s premier international showcase for financial dealmakers and biopharma executives to meet rising biotechs.

China BIO Partnering Forum

Event / By
Engage with the largest network of potential partners to accelerate your cross-border strategies and expand your reach into the China market.

Anticancer Bioscience Announces CNY63m (~USD10m) Financing to Advance its Synthetic Lethal Platform and Pre-clinical Oncology Pipeline

Leave a Comment / Press Releases / By
In the NewsFebruary 8, 2021Anticancer Bioscience Announces CNY63m (~USD10m) Financing to Advance its Synthetic Lethal Platform and Pre-clinical Oncology Pipeline Chengdu, China, 8 February 2021 - Anticancer Bioscience (ACB), pioneers in synthetic lethal approaches to precision oncology, announced today that having successfully closed an additional financing round, raising CNY63m (~USD10m), it has already achieved positive …

Anticancer Bioscience Announces CNY63m (~USD10m) Financing to Advance its Synthetic Lethal Platform and Pre-clinical Oncology Pipeline Read More »